T80.A11S Non-ABO incompatibility with delayed hemolytic transfusion reaction, sequela

Name of the Condition

• Non-ABO incompatibility with delayed hemolytic transfusion reaction, sequela.

Summary

This condition represents the long-term consequences (sequela) of a delayed hemolytic transfusion reaction resulting from non-ABO blood group incompatibility. It occurs when the recipient’s immune system reacts to non-ABO antigens in transfused blood or blood products, leading to hemolysis that manifests days to weeks after the transfusion. The sequela reflects persistent or residual effects of the initial immune-mediated destruction of transfused red blood cells, which may include ongoing clinical symptoms, laboratory abnormalities, or organ involvement.

Causes

The sequela of a delayed hemolytic transfusion reaction due to non-ABO incompatibility arises from prior immune responses to minor blood group antigens (e.g., Rh, Kell, Duffy, Kidd) present in donor blood. These reactions are triggered by antibodies developed through prior sensitization, such as pregnancy, previous transfusions, or organ transplants. The initial transfusion of incompatible blood leads to delayed immune activation and red blood cell lysis, with residual effects persisting as the sequela.

Risk Factors

• Prior exposure to non-ABO antigens (e.g., through pregnancy or previous transfusions)
• History of multiple transfusions
• Underlying immune-mediated conditions
• Use of blood products with non-ABO antigen mismatches
• Lack of pre-transfusion antibody screening in high-risk patients

Symptoms

• Persistent fatigue or weakness
• Jaundice or elevated bilirubin levels
• Dark urine (hemoglobinuria)
• Recurrent or unresolved anemia
• Mild to moderate fever
• Flank pain or back discomfort
• Elevated lactate dehydrogenase (LDH) levels

Diagnosis

Diagnosis of the sequela involves reviewing the patient’s transfusion history and prior reaction, along with current clinical and laboratory findings. Key indicators include persistent hemolysis markers (e.g., elevated LDH, indirect bilirubin, reticulocytosis) and evidence of ongoing immune activity. Direct antiglobulin testing (Coombs test) may show residual antibody activity, and imaging or organ function tests may assess for long-term complications (e.g., renal impairment).

Treatment Options

Management focuses on addressing residual symptoms and preventing further complications. This may include monitoring for anemia, supporting renal function, and avoiding future incompatible transfusions. In some cases, immunosuppressive therapy or plasmapheresis may be considered to reduce ongoing immune activity. Supportive care, such as hydration and symptom management, is often sufficient.

Prognosis and Follow-Up

The prognosis for this sequela is generally favorable with appropriate management, though residual effects may persist. Regular follow-up is recommended to monitor for delayed complications, such as chronic anemia or organ damage. Most patients recover fully, but long-term surveillance ensures early detection of any adverse outcomes.

Complications

• Chronic anemia requiring ongoing management
• Renal impairment or failure
• Persistent immune sensitization increasing future transfusion risks
• Delayed organ damage (e.g., hepatic or splenic involvement)

Lifestyle & Prevention

• Ensure accurate blood typing and crossmatching before transfusions.
• Maintain a record of prior transfusion reactions or sensitization events.
• Follow up with healthcare providers after transfusions to report any delayed symptoms.
• Avoid unnecessary transfusions to minimize exposure to non-ABO antigens.

When to Seek Professional Help

Seek medical attention if you experience persistent fatigue, jaundice, dark urine, or unexplained anemia after a transfusion. These symptoms may indicate a delayed reaction or its sequela, requiring prompt evaluation to prevent complications.

Tips for Medical Coders

Code T80.A11S is used for the sequela of a delayed hemolytic transfusion reaction due to non-ABO incompatibility. Document the causal relationship between the prior transfusion reaction and the current condition, including clinical evidence of residual effects. Ensure the code is applied only when the sequela is directly attributable to the initial non-ABO incompatibility and not to other causes.